EA201992522A1 - КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ - Google Patents
КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫInfo
- Publication number
- EA201992522A1 EA201992522A1 EA201992522A EA201992522A EA201992522A1 EA 201992522 A1 EA201992522 A1 EA 201992522A1 EA 201992522 A EA201992522 A EA 201992522A EA 201992522 A EA201992522 A EA 201992522A EA 201992522 A1 EA201992522 A1 EA 201992522A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- erbb
- combination
- breast cancer
- endocrine therapy
- specific antibody
- Prior art date
Links
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 101150029707 ERBB2 gene Proteins 0.000 title abstract 2
- 238000009261 endocrine therapy Methods 0.000 title abstract 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к способам лечения субъекта, страдающего от рака молочной железы или подверженного риску развития указанного рака, включающим введение субъекту, нуждающемуся в этом, комбинации терапевтически эффективного количества биспецифического антитела к ErbB-2/ErbB-3 и терапевтически эффективного количества лекарственного средства для эндокринной терапии, причем указанное биспецифическое антитело имеет антигенсвязывающий сайт, который может связывать внеклеточную часть ErbB-2, и антигенсвязывающий сайт, который может связывать внеклеточную часть ErbB-3; а также к средствам для применения в указанном способе.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507675P | 2017-05-17 | 2017-05-17 | |
PCT/NL2018/050329 WO2018212656A1 (en) | 2017-05-17 | 2018-05-17 | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992522A1 true EA201992522A1 (ru) | 2020-04-22 |
Family
ID=62716109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992522A EA201992522A1 (ru) | 2017-05-17 | 2018-05-17 | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210054096A1 (ru) |
EP (1) | EP3625264B9 (ru) |
JP (2) | JP7296891B2 (ru) |
KR (1) | KR20200018785A (ru) |
CN (1) | CN111148764A (ru) |
AU (1) | AU2018271157C1 (ru) |
BR (1) | BR112019024230A2 (ru) |
CA (1) | CA3063849A1 (ru) |
EA (1) | EA201992522A1 (ru) |
ES (1) | ES2951864T3 (ru) |
IL (1) | IL270716B2 (ru) |
MX (1) | MX2019013804A (ru) |
PH (1) | PH12019502574A1 (ru) |
WO (1) | WO2018212656A1 (ru) |
ZA (1) | ZA201907754B (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3365373B1 (en) | 2015-10-23 | 2021-03-10 | Merus N.V. | Binding molecules that inhibit cancer growth |
EP3600413A1 (en) | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
EP3456190B1 (en) | 2008-06-27 | 2021-11-24 | Merus N.V. | Antibody producing transgenic murine animal |
SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
WO2012116317A2 (en) * | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
EP2683741A2 (en) * | 2011-03-11 | 2014-01-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
KR20200126007A (ko) | 2012-04-20 | 2020-11-05 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
EP3074424A4 (en) * | 2013-11-27 | 2017-06-14 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
IL301147A (en) * | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
-
2018
- 2018-05-17 MX MX2019013804A patent/MX2019013804A/es unknown
- 2018-05-17 CN CN201880042060.6A patent/CN111148764A/zh active Pending
- 2018-05-17 CA CA3063849A patent/CA3063849A1/en active Pending
- 2018-05-17 WO PCT/NL2018/050329 patent/WO2018212656A1/en unknown
- 2018-05-17 US US16/614,237 patent/US20210054096A1/en active Pending
- 2018-05-17 AU AU2018271157A patent/AU2018271157C1/en active Active
- 2018-05-17 EA EA201992522A patent/EA201992522A1/ru unknown
- 2018-05-17 ES ES18733959T patent/ES2951864T3/es active Active
- 2018-05-17 KR KR1020197037337A patent/KR20200018785A/ko active Search and Examination
- 2018-05-17 EP EP18733959.3A patent/EP3625264B9/en active Active
- 2018-05-17 JP JP2019563855A patent/JP7296891B2/ja active Active
- 2018-05-17 BR BR112019024230A patent/BR112019024230A2/pt not_active IP Right Cessation
-
2019
- 2019-11-17 IL IL270716A patent/IL270716B2/en unknown
- 2019-11-18 PH PH12019502574A patent/PH12019502574A1/en unknown
- 2019-11-22 ZA ZA2019/07754A patent/ZA201907754B/en unknown
-
2023
- 2023-04-03 JP JP2023060123A patent/JP2023085422A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12019502574A1 (en) | 2020-12-07 |
CA3063849A1 (en) | 2018-11-22 |
WO2018212656A1 (en) | 2018-11-22 |
ZA201907754B (en) | 2023-11-29 |
MX2019013804A (es) | 2020-02-24 |
IL270716A (en) | 2020-01-30 |
JP2023085422A (ja) | 2023-06-20 |
KR20200018785A (ko) | 2020-02-20 |
EP3625264B1 (en) | 2023-06-28 |
ES2951864T3 (es) | 2023-10-25 |
JP7296891B2 (ja) | 2023-06-23 |
AU2018271157B2 (en) | 2021-06-17 |
BR112019024230A2 (pt) | 2020-06-09 |
AU2018271157C1 (en) | 2021-11-18 |
EP3625264B9 (en) | 2023-10-25 |
ES2951864T9 (es) | 2023-11-29 |
JP2020520377A (ja) | 2020-07-09 |
US20210054096A1 (en) | 2021-02-25 |
AU2018271157A1 (en) | 2019-12-05 |
IL270716B2 (en) | 2023-02-01 |
IL270716B (en) | 2022-10-01 |
CN111148764A (zh) | 2020-05-12 |
EP3625264A1 (en) | 2020-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550023A1 (en) | Humanized anti-tau antibodies | |
EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
PE20180795A1 (es) | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
GEP20197034B (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201490622A1 (ru) | Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201891925A1 (ru) | Антитела к cd40 с усиленной агонистической активностью | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
MX2021000783A (es) | Anticuerpos humanizados contra psma. | |
EA202090791A1 (ru) | Агонистические антитела против cd40 | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
MX2020009902A (es) | Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos. | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
EA201791970A1 (ru) | Способ лечения первичного склерозирующего холангита | |
EA201992522A1 (ru) | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
EA201891800A1 (ru) | Антитела к цитруллинированным hla-полипептидам и их применение |